• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

银屑病的遗传易感性及相关基因与治疗选择的关系。

The Genetic Susceptibility to Psoriasis and the Relationship of Linked Genes to Our Treatment Options.

机构信息

Center for Dermatology Research, Wake Forest School of Medicine, Winston-Salem, NC 27104, USA.

The Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

出版信息

Int J Mol Sci. 2023 Aug 1;24(15):12310. doi: 10.3390/ijms241512310.

DOI:10.3390/ijms241512310
PMID:37569685
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10418823/
Abstract

Understanding the factors creating genetic susceptibility in psoriasis may provide a basis for improving targeted treatment strategies. In this review, we discuss the genes linked to the pathogenesis of psoriasis and their relationship to the available treatment options. To identify the relevant genetic markers and treatments, we searched PubMed, Google Scholar, MEDLINE, and Web of Science with keywords, including , , , and . The articles in English from database inception to 1/1/23 were included. Case reports and series were excluded. Gene variant forms commonly implicated in the pathogenesis of psoriasis include those encoding for interleukins, interferons, and other mediators involved in inflammatory pathways, such as JAK/STAT, and NF-κB. Several of the treatments for psoriasis (for example IL23 and TYK2 inhibitors) target the products of genes linked to psoriasis. Multiple genes are linked to the pathogenesis of psoriasis. This understanding may provide an avenue for the development of new psoriasis treatment strategies and for more effective, safer treatment outcomes.

摘要

了解导致银屑病遗传易感性的因素可能为改善靶向治疗策略提供基础。在这篇综述中,我们讨论了与银屑病发病机制相关的基因及其与现有治疗选择的关系。为了确定相关的遗传标志物和治疗方法,我们使用关键词在 PubMed、Google Scholar、MEDLINE 和 Web of Science 上进行了搜索,包括 、 、 、 。纳入了从数据库建立到 2023 年 1 月 1 日的英文文章。排除了病例报告和系列。在银屑病发病机制中常见的基因变异形式包括编码白细胞介素、干扰素和其他参与炎症途径的介质的基因,如 JAK/STAT 和 NF-κB。几种银屑病治疗方法(例如 IL23 和 TYK2 抑制剂)针对与银屑病相关的基因产物。多个基因与银屑病的发病机制有关。这种认识可能为开发新的银屑病治疗策略以及更有效、更安全的治疗结果提供途径。

相似文献

1
The Genetic Susceptibility to Psoriasis and the Relationship of Linked Genes to Our Treatment Options.银屑病的遗传易感性及相关基因与治疗选择的关系。
Int J Mol Sci. 2023 Aug 1;24(15):12310. doi: 10.3390/ijms241512310.
2
New Biologics and Oral Drugs in Treatment of Moderate to Severe Psoriasis.新型生物制剂和口服药物治疗中重度银屑病。
J Drugs Dermatol. 2022 Aug 1;21(8):826-831. doi: 10.36849/JDD.6443.
3
Inhibition of TYK2 and JAK1 ameliorates imiquimod-induced psoriasis-like dermatitis by inhibiting IL-22 and the IL-23/IL-17 axis.抑制 TYK2 和 JAK1 通过抑制 IL-22 和 IL-23/IL-17 轴改善咪喹莫特诱导的银屑病样皮炎。
J Immunol. 2014 Oct 1;193(7):3278-87. doi: 10.4049/jimmunol.1400205. Epub 2014 Aug 25.
4
From Empirical to Pathogenesis-Based Treatments for Psoriasis.从经验性治疗到基于发病机制的银屑病治疗。
J Invest Dermatol. 2022 Jul;142(7):1778-1785. doi: 10.1016/j.jid.2022.01.014. Epub 2022 Mar 3.
5
Advances in psoriasis research: From pathogenesis to therapeutics.银屑病研究进展:从发病机制到治疗学。
Life Sci. 2024 Oct 15;355:122991. doi: 10.1016/j.lfs.2024.122991. Epub 2024 Aug 15.
6
An update on genetic basis of generalized pustular psoriasis (Review).泛发性脓疱型银屑病的遗传学基础研究进展(综述)。
Int J Mol Med. 2021 Jun;47(6). doi: 10.3892/ijmm.2021.4951. Epub 2021 May 6.
7
TYK2 as a novel therapeutic target in psoriasis.TYK2 作为银屑病的一个新的治疗靶点。
Expert Rev Clin Pharmacol. 2023 Jan-Jun;16(6):549-558. doi: 10.1080/17512433.2023.2219054. Epub 2023 Jun 7.
8
English version of Japanese guidance for the use of oral Janus kinase inhibitors (JAK1 and TYK2 inhibitors) in the treatments of psoriasis.日本指导意见的英文版本,用于口服 Janus 激酶抑制剂(JAK1 和 TYK2 抑制剂)治疗银屑病。
J Dermatol. 2023 May;50(5):e138-e150. doi: 10.1111/1346-8138.16797. Epub 2023 Apr 1.
9
JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors.JAK 抑制剂治疗银屑病:聚焦于选择性 TYK2 抑制剂。
Drugs. 2020 Mar;80(4):341-352. doi: 10.1007/s40265-020-01261-8.
10
Treatment Options and Goals for Patients with Generalized Pustular Psoriasis.泛发性脓疱型银屑病患者的治疗选择和目标。
Am J Clin Dermatol. 2022 Jan;23(Suppl 1):51-64. doi: 10.1007/s40257-021-00658-9. Epub 2022 Jan 21.

引用本文的文献

1
Systemic Psoriasis: From Molecular Mechanisms to Global Management Strategies.全身性银屑病:从分子机制到全球管理策略
Clin Rev Allergy Immunol. 2025 Aug 7;68(1):79. doi: 10.1007/s12016-025-09089-4.
2
Co-occurrence of endometriosis with psoriasis and psoriatic arthritis: Genetic insights (Review).子宫内膜异位症与银屑病及银屑病关节炎的共病现象:遗传学见解(综述)
Exp Ther Med. 2025 Jul 10;30(3):171. doi: 10.3892/etm.2025.12921. eCollection 2025 Sep.
3
Erythrodermic Psoriasis in the Context of Emerging Triggers: Insights into Dupilumab-Associated and COVID-19-Induced Psoriatic Disease.新发触发因素背景下的红皮病型银屑病:度普利尤单抗相关及新冠病毒诱导的银屑病性疾病解析
Dermatopathology (Basel). 2025 Jun 9;12(2):17. doi: 10.3390/dermatopathology12020017.
4
The M2 Macrophages Importance Role in Psoriasis.M2巨噬细胞在银屑病中的重要作用
Immun Inflamm Dis. 2025 Jun;13(6):e70211. doi: 10.1002/iid3.70211.
5
Factors associated with a better treatment efficacy among psoriasis patients: a study based on decision tree model and logistic regression in Shanghai, China.与银屑病患者治疗效果更好相关的因素:基于决策树模型和 logistic 回归的在中国上海开展的研究。
BMC Public Health. 2024 Jul 18;24(1):1934. doi: 10.1186/s12889-024-19468-9.

本文引用的文献

1
Spesolimab: First Approval.斯帕斯单抗:首次批准。
Drugs. 2022 Nov;82(17):1681-1686. doi: 10.1007/s40265-022-01801-4.
2
Deucravacitinib: First Approval.地达西布替尼:首次获批
Drugs. 2022 Nov;82(17):1671-1679. doi: 10.1007/s40265-022-01796-y.
3
Genetics of psoriasis: a basis for precision medicine.银屑病的遗传学:精准医学的基础
Precis Clin Med. 2019 Jun 24;2(2):120-130. doi: 10.1093/pcmedi/pbz011. eCollection 2019 Jun.
4
Pustular Psoriasis: From Pathophysiology to Treatment.脓疱型银屑病:从病理生理学到治疗
Biomedicines. 2021 Nov 23;9(12):1746. doi: 10.3390/biomedicines9121746.
5
Trial of Spesolimab for Generalized Pustular Psoriasis.特索利单抗治疗泛发性脓疱型银屑病的试验。
N Engl J Med. 2021 Dec 23;385(26):2431-2440. doi: 10.1056/NEJMoa2111563.
6
The Cytokine Mediated Molecular Pathophysiology of Psoriasis and Its Clinical Implications.细胞因子介导的银屑病分子病理生理学及其临床意义。
Int J Mol Sci. 2021 Nov 26;22(23):12793. doi: 10.3390/ijms222312793.
7
Psoriasis.银屑病。
Lancet. 2021 Apr 3;397(10281):1301-1315. doi: 10.1016/S0140-6736(20)32549-6.
8
Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study.司妥昔单抗(一种抗白细胞介素-36受体抗体)治疗掌跖脓疱病患者:一项IIa期、多中心、双盲、随机、安慰剂对照试验的结果
Dermatol Ther (Heidelb). 2021 Apr;11(2):571-585. doi: 10.1007/s13555-021-00504-0. Epub 2021 Mar 4.
9
The TNF/IL-23/IL-17 axis-Head-to-head trials comparing different biologics in psoriasis treatment.TNF/IL-23/IL-17 轴——头对头试验比较不同生物制剂治疗银屑病的疗效。
Scand J Immunol. 2020 Oct;92(4):e12946. doi: 10.1111/sji.12946.
10
Current Developments in the Immunology of Psoriasis.银屑病免疫学的最新进展。
Yale J Biol Med. 2020 Mar 27;93(1):97-110. eCollection 2020 Mar.